GCM
REGN icon

Gladius Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Gladius Capital Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-30,000
Closed -$21.6M – 433
2023
Q2 		$21.6M Sell
30,000
-30,000
-50% -$23.1M 1.05% 19
2023
Q1 		$49.3M Buy
+60,000
New +$45.3M 2.87% 8

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Gladius Capital Management's REGN Position: Q3 2023 in Review

Gladius Capital Management sold out of Regeneron Pharmaceuticals (REGN) in Q3 2023, closing a stake of 8,150 shares — an estimated $5.86M sold.

Gladius Capital Management first reported a position in REGN in Q4 2021 and held it in 4 quarters. The position peaked at $5.86M in Q2 2023. 1,177 funds tracked by Wall St. Rank hold REGN as of Q3 2023.

  • Gladius Capital Management reported no remaining Regeneron Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Gladius Capital Management sold 8,150 Regeneron Pharmaceuticals shares in Q3 2023, an estimated $5.86M.
  • Gladius Capital Management first reported a position in Regeneron Pharmaceuticals in Q4 2021 and held it in 4 quarters.
  • Gladius Capital Management's Regeneron Pharmaceuticals position peaked at $5.86M in Q2 2023.
  • 1,177 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2023.

Based on Gladius Capital Management's 13F filing for Q3 2023, filed 10 Oct 2023.